Nilai Dipunlarasaken Utang lan Kas Cellectar Corp (CLRB)

The market trend for Cellectar Biosciences (CLRB) demonstrates an Enterprise Value of -21.02. This price action is based on the completion of medical trials with no current merger plans. The business's success relies on the precision of isotope transport into neoplasms via phospholipids. Cellectar Biosciences (CLRB) generates revenue from the sale of radiopharmaceuticals in specialized centers, where payments are provided by government programs and insurance funds.

CLRB Cellectar Biosciences, Inc.: Nilai Perusahaan ing interval 23.11.2025 - 28.10.2026

CLRB (Cellectar Biosciences): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:

Bagan rega Cellectar Biosciences Inc|CLRB - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar Cellectar Biosciences|CLRB - Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Cellectar Biosciences|CLRB - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas cellectar.com|CLRB - Total Aset Perusahaan

- data utang lan likuiditas:

Utang marang Modal Cellectar Biosciences|CLRB - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal cellectar.com|CLRB - Gunggung utang perusahaan|Utang-utang marang nilai buku Cellectar Biosciences

Pambiji fundamental:Cellectar Biosciences Inc (CLRB)

Produk sing diprodhuksi Cellectar Biosciences Inc

Enterprise value is calculated by summing market capitalization and debt obligations minus cash and cash equivalents. This metric determines the actual cost of a full business buyout. For Cellectar Biosciences (CLRB), this figure reflects financial pressure stemming from drug launch costs and FDA regulatory risks. By analyzing the enterprise value chart, an investor can see the real scale of the company's valuation.

Analisis perusahaan pesaing